Skip to main content
. 2019 May 27;19:498. doi: 10.1186/s12885-019-5732-z

Table 2.

Clinicopathological characteristics and comparison of clinicopathological characteristics with mrEMVI status

Clinicopathological characteristics Total mrEMVI (−) mrEMVI (+) P
n = 72 (100%) n = 47 (65.3%) n = 25 (34.7%)
Age, mean ± SD 60 ± 10 61 ± 10 58 ± 10 0.214a
Gender 0.537b
 Male 41 (56.9%) 28 (59.6%) 13 (52.0%)
 Female 31 (43.1%) 19 (40.4%) 12 (48.0%)
Tumour location# 0.355b
 Lower 13 (18.1%) 10 (21.3%) 3 (12.0%)
 Middle 32 (44.4%) 22 (46.8%) 10 (40.0%)
 Upper 27 (37.5%) 15 (31.9%) 12 (48.0%)
Tumour size (cm), median (range) 3.0 (0.3–6.0) 2.9 (0.3–6.0) 3.5 (1.8–6.0) 0.011c*
Differentiation 0.234d
 Well 1 (1.4%) 1 (2.1%) 0 (0.0%)
 Moderate 60 (83.3%) 41 (87.2%) 19 (76.0%)
 Poor 11 (15.3%) 5 (10.6%) 6 (24.0%)
Pathological T stage 0.010b*
 T1–2 19 (26.4%) 17 (36.2%) 2 (8.0%)
 T3–4 53 (73.6%) 30 (63.8%) 23 (92.0%)
Pathological N stage 0.001b*
 N0 36 (50.0%) 30 (63.8%) 6 (24.0%)
 N1–2 36 (50.0%) 17 (36.2%) 19 (76.0%)
Synchronous distant metastasis 0.426b
 Negative 51 (91.1%) 35 (94.6%) 16 (84.2%)
 Positive 5 (8.9%) 2 (5.4%) 3 (15.8%)

mrEMVI magnetic resonance imaging-detected extramural vascular invasion, SD standard deviation, T tumour, N node

#According to the distance from the most caudal border of the rectal tumour to the anal verge on MRI: lower, < 5 cm; middle 5–10 cm; upper, > 10 cm

aindependent samples t-test, bχ2 test, cMann-Whitney U test, dFisher’s exact test, *indicates significant difference